Allergic Rhinitis Clinical Trial
Official title:
Analysis of Immunological Reactions to Pollen-Related Foods in Birch Pollen-Allergic Patients
A high number of birch pollen-allergic individuals develop hypersensitivity reactions to
certain foods, e.g. apples. This food allergy is due to immunological cross-reactivity.
Birch pollen-related foods contain proteins, e.g. Mal d 1 in apple, that are structurally
related with the major birch pollen allergen, Bet v 1. Hence IgE antibodies and T
lymphocytes specific for Bet v 1 recognize these food proteins which results in activation
of the immune system and, consequently, in clinical symptoms.
In the present study the investigators intend to investigate if and how the consumption of
birch pollen-related food allergens affects birch pollen allergy. In other words, the
investigators are interested to analyse whether Bet v 1-related food allergens activate Bet
v 1-specific memory cells and thus, contribute to the maintenance of the pollen allergy
outside the pollen season. Data obtained in this study will help to clarify the
immunological and clinical role of cross-reactivity between pollen and food allergies and
will reveal whether avoidance of such foods should be recommended for the patients. Finally,
novel approaches for diagnosis and therapy of pollen-related food allergens can be
developed.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | December 2010 |
Est. primary completion date | January 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Otherwise healthy birch pollen allergic (rhinoconjunctivitis)persons - Positive SPT and RAST to birch pollen - Sensitized to Bet v 1 Exclusion Criteria: - Persons suffering from malignancies, autoimmune and cardiopulmonary diseases - Anemia - Hyper-IgE syndrome - Treatment with ß-blockers, permanent treatment with antihistaminics, leucotriene antagonists, corticosteroids |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05080322 -
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
|
Phase 4 | |
Recruiting |
NCT06028490 -
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
|
Phase 2 | |
Completed |
NCT04388358 -
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
|
N/A | |
Recruiting |
NCT04202263 -
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
|
Phase 2 | |
Completed |
NCT04078009 -
Standardising Nasal Allergen Challenge in Adult With Hay Fever
|
N/A | |
Completed |
NCT03644680 -
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
|
N/A | |
Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
Recruiting |
NCT05378594 -
HDM and Silver Birch NAC Standardisation
|
N/A | |
Not yet recruiting |
NCT05684380 -
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
|
Phase 3 | |
Not yet recruiting |
NCT01014325 -
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
|
Phase 3 | |
Completed |
NCT02943720 -
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
|
Phase 2 | |
Completed |
NCT02910401 -
Clinical Response to Rhinovirus Challenge
|
Phase 2 | |
Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
Not yet recruiting |
NCT02233426 -
Effect of Hypertonic Solutions on Allergic Rhinitis Patients
|
N/A | |
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
Completed |
NCT01946035 -
Alpha-Blockers in Allergic Rhinitis (MAN 01)
|
Phase 4 | |
Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
Recruiting |
NCT01454492 -
The Relationship Between Allergic Rhinitis and Geographic Tongue
|
N/A | |
Completed |
NCT01439815 -
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
|
Phase 4 |